Installation of the first XPS™ in Asia

Medcor LLP has purchased an XVIVO Perfusion System (XPS™). Medcor will cooperate
in the establishment of a new clinical program for lung transplantation and Ex
Vivo Lung Perfusion (EVLP) in Almaty, Kazakhstan.  This is the first XPS™ sold
in Asia.
Strategic collaborations between University Hospitals in Kazakhstan with
prestigious Universities in the U.S. and Europe have resulted in unique
collaborations to improve health care quality through exchange of knowledge and
skills in a variety of areas, including lung transplantation. Lung
transplantation is the only therapeutic option for selected patients suffering
from end stage lung diseases. Earlier this year, Kazakhstan Vice-Minister of
Healthcare Erik Baizhunussov, announced that the first lung transplantation will
be made in Kazakhstan in 2014.

“We are ready for this type of transplantation. There are many patients who need
this surgery as no other kind of surgery can save them. I think that we will be
able to begin this surgery in 2014,” said Mr Baizhunussov.

At present, Asia accounts for less than five percent of the total number of lung
transplants carried out in the world, but with increased economic opportunities,
the number of lung transplants may increase. In instituting the STEEN Solution™
method with XPS™ early in these markets, this development can occur more rapidly
than would otherwise be possible.

“It is a great pleasure to note that the XPS™ will be used to support the
establishment of a new clinical program for lung transplantation in Asia. This
is a great step forward to establish EVLP throughout the globe”, says Mr
Christer de Flon, Marketing & Sales Director, XVIVO Perfusion.

September 30, 2014
Gothenburg
XVIVO Perfusion AB (publ)
Magnus Nilsson
CEO
For further information please contact:
Christoffer Rosenblad, CFO, +46 31 788 21 59,
christoffer.rosenblad@xvivoperfusion.com
For further information on XVIVO Perfusion’s business, please refer to the
company’s website, www.xvivoperfusion.com

The information was submitted for publication on September 30, 2014 at 2:30 p.m.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.
________________________________________________________________________________
_ 
_____________________________________

XVIVO Perfusion AB is a medical technology company which develops solutions and
systems for assessing and preserving organs outside the body and for selecting
usable organs and maintaining them in optimal condition pending transplantation.
The company is headquartered in Gothenburg, Sweden, and has one office in the
USA. The XVIVO share is listed on NASDAQ OMX First North and has the ticker
symbol XVIVO. More information can be found on the website
www.xvivoperfusion.com. The Certified Adviser is Redeye, www.redeye.se.
________________________________________________________________________________
_ 
_____________________________________

XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity
number 556561-0424.
Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com